Interleukin Genetics, Inc. and Stanford University Report Genetic Test Improves Weight Loss Success With Diets
03 Marzo 2010 - 12:55PM
PR Newswire (US)
WALTHAM, Mass., March 3 /PRNewswire-FirstCall/ -- Interleukin
Genetics, Inc. (NYSE Amex: ILI) announced presentation of findings
from a retrospective clinical study on weight management conducted
in collaboration with Stanford University. The study results and
conclusions were presented today by investigators from Stanford
Prevention Research Center at Stanford University School of
Medicine during an oral presentation titled "Genotype Patterns
Predict Weight Loss Success: The Right Diet Does Matter," at the
American Heart Association's Joint 50th Cardiovascular Disease
Epidemiology and Prevention - and - Nutrition, Physical Activity
and Metabolism conference, being held March 2-5 in San Francisco,
CA. In 2008, Interleukin Genetics and Stanford University began a
research collaboration to determine whether individuals who were
assigned diets that were appropriate for their genotype could lose
more weight than those who followed a diet inappropriate for their
genotype, as determined by the Interleukin Genetics proprietary
Weight Management Genetic Test. The findings showed statistically
significant greater weight loss, metabolic benefit and other
improvements when compared to individuals on diets not matched to
their genotype. Key Stanford findings from the study include: --
Individuals on genotype-appropriate diets lost 5.3 percent of body
weight compared to individuals on diets not matched to their
genotype, who experienced only 2.3 percent weight loss (p=0.005);
-- The weight loss differences were even stronger when considering
the individuals who were trying to follow the lowest carbohydrate
(Atkins) and the lowest fat (Ornish) diets: 6.8% weight loss for
those whose genotype matched the diet they were following vs. 1.4%
for those not matched to their genotype (p=0.03); -- The
statistical significance of the findings increased when taking into
account the actual diet habits reported by study participants
(rather than just the specific diet they were asked to follow); --
Improvements in clinical measures related to weight loss (e.g.,
blood triglyceride levels) paralleled the weight loss differences.
"The differentiation in weight loss observed for individuals who
followed a diet matched to their genotype versus one that was not
matched to their genotype is highly significant in numerous
categories and represents an approach to weight loss that has not
been previously reported in the literature," said Christopher
Gardner, Ph.D., Director of Nutrition Studies at the Stanford
Prevention Research Center and an Associate Professor of Medicine
at Stanford University. "The potential of using genetic information
to achieve this magnitude of weight loss without pharmaceutical
intervention would be important in helping to solve the pervasive
problem of excessive weight in our society. We are eager to
follow-up on this study and to determine the magnitude of health
benefits that may result from following a diet that is matched to
one's genotype." "We're pleased our research has been selected for
presentation at this important scientific meeting," said
Interleukin Genetics Chief Scientific Officer Kenneth Kornman.
"Results from this study are compelling and indicate strong
potential for broad utility of a genetic test to guide diet and
lifestyle choices." About the Study Subjects for the study were
chosen from Stanford University's previously reported A TO Z weight
loss study (Gardner et al. 2007 J. American Medical Association),
which compared effectiveness of four weight loss diets ranging from
very low carbohydrate, to low carbohydrate/high protein, to low fat
and to very low fat in overweight/obese pre-menopausal women over a
one-year period. Participants from the A TO Z trial were invited by
e-mail and postal mail to provide DNA samples by cheek swab.
Genotyping was performed on the DNA samples obtained from 141
female participants. Participants were categorized into three
dietary assignment groups including: a) low fat, b) low
carbohydrate, or c) balanced in macronutrients by means of
predefined genetic patterns from the Inherent Health Weight
Management Genetic Test. The primary endpoint analysis compared
weight loss for women who were on a diet that was consistent with
their genotype category to those individuals on diets not suitable
for their genetic pattern. Interleukin Genetics, Inc. reported
initial analysis of data from this A TO Z study in September. About
Interleukin Genetics Interleukin Genetics, Inc. (NYSE Amex: ILI)
develops and markets genetic tests that empower consumers to
prevent chronic diseases of aging and that assist pharmaceutical
companies in the development and marketing of targeted
therapeutics. The Company leverages its research, intellectual
property and biomarker development experience to facilitate the
emerging personalized health market. Interleukin Genetics is
headquartered in Waltham, MA. The Weight Management Test is a
proprietary genetic test panel developed by Interleukin Genetics
that analyzes single nucleotide variations among several functional
genes to create macronutrient percentage diet and exercise
recommendations for the individual. The test is marketed under the
Inherent Health brand (http://www.inherenthealth.com/) and is
analyzed in Interleukin Genetics' CLIA-certified laboratory. For
more information please visit http://www.ilgenetics.com/. Certain
statements contained herein are "forward-looking" statements
including statements regarding the potential utility of the
Company's Weight Management Genetic Test. Because such statements
include risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to, the risk of market
acceptance of the Company's products, the risk of technology and
product obsolescence, delays in product development, the
performance of commercial partners, the availability of adequate
capital, the actions of competitors and other competitive risks,
and those risks and uncertainties described in the Company's annual
report on Form 10-K for the year ended December 31, 2008, quarterly
reports on Form 10-Q and other filings with the Securities and
Exchange Commission. The Company disclaims any obligation or
intention to update these forward-looking statements. DATASOURCE:
Interleukin Genetics, Inc. CONTACT: Media, Erin Walsh of
Interleukin Genetics, +1-617-281-8184,ewalsh@ilgenetics.com Web
Site: http://www.ilgenetics.com/
Copyright
Imagelinx (LSE:ILI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Imagelinx (LSE:ILI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Imagelinx (London Stock Exchange): 0 recent articles
Más de Imagelinx Artículos de Noticias